case_images: PMC10794297_01
case_images: Clinical timeline.
case_images: fonc-13-1267650-g001.jpg
case_images: PMC10794297_01_fonc-13-1267650-g001.jpg
case_images: f1
case_images: The patient received three cycles of neoadjuvant chemotherapy with taxol and carboplatin, followed by an exploratory laparotomy, radical resection for tumor debulking, total abdominal hysterectomy, bilateral salpingo-oophorectomy, rectosigmoid resection, partial resection of the transverse colon with re-anastomosis, partial ileal resection with re-anastomosis, and descending colostomy in October of 2016 ( Figure 1 ). Overall, since the start of fulvestrant and subsequent addition of everolimus 2 months later, the patient's CA-125 level stabilized ( Figure 1 ), and she experienced disease control for 7 months and an overall survival of 11 months.
case_images: (A) Summary of tumor molecular profiling findings with therapeutic implications. *ESR1 mutation was confirmed in organoids. (B) PARIS  drug sensitivity assay workflow, including organoid generation from core biopsy, characterization, and report generation. Figure generated using Biorender. (C) Brightfield photomicrograph of the patient's cultured tumor organoids. Scale bar = 10 microm. (D) Table of top-scoring drugs in green from the PARIS  assay.
case_images: fonc-13-1267650-g002.jpg
case_images: PMC10794297_01_fonc-13-1267650-g002.jpg
case_images: f2
case_images: Further molecular testing (Caris MI Profile) on a right flank tissue sample from October 2018, after 9 months of letrozole, showed that the sample was ER positive, PR negative, and had acquired a somatic pathogenic alteration in the ESR1 gene (Y537S), suggesting a possible resistance mechanism to letrozole ( Figure 2A ). In December 2018, a core biopsy from an abdominal wall metastasis was obtained and shipped to SEngine Precision Medicine ( Figures 2B, C ).